TCR cell therapy for melanoma and head and neck cancer
Part of Cancer, Eyes & vision, Skin clinical trials.
This early-phase study tests a lab-made T-cell treatment that targets a specific tumor marker (MC2) in melanoma and head and neck cancers. It aims to see if the treatment can safely shrink tumors and control cancer after standard options have run out.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older and can sign an informed consent form
- Your cancer is either melanoma, uveal melanoma, or metastatic head and neck cancer—and standard treatment is no longer an option
- Your tumor tests positive for MC2 (more than 5% of tumor cells) from a biopsy (archival or new)
- You have the HLA-A2*02:01 blood type, and you must have measurable tumors on scans
- You must be able to get planned tumor biopsies and be well enough for study treatment (ECOG 0–1)
- Recent standard therapy must have been tried and cancer must have progressed (timing limits apply)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
This Phase 1 study tests a lab-made immune cell treatment for advanced melanoma. It aims to see if engineered T-cells can recognize the patient’s tumor and help control the cancer, especially in specific melanoma tissue markers.
This study tests a new type of CAR-T cell therapy that targets a protein called Trop2 found on some head and neck cancer cells. It's for people who have tried standard treatments and need a new option.
This trial tests a new treatment for advanced melanoma that can be surgically removed. It combines your own immune cells (called gamma-delta T cells) with a drug (interferon or a PD-1 blocker) to see if it helps the body fight the cancer before and after surgery.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.